Vitamin B3 and Improved Progression-free Survival

Doses used in studies

Safety in these studies

flushingReported
The most common side effect was flushing (10/15; 9 grade 1).
from: A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and int
hyperbilirubinemiaReportedSerious adverse eventTwo DLTs occurred at 2,500 mg/d niacin (grade 3 thrombocytopenia and hyperbilirubinemia).
Two DLTs occurred at 2,500 mg/d niacin (grade 3 thrombocytopenia and hyperbilirubinemia).
from: A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and int
thrombocytopeniaReportedSerious adverse eventTwo DLTs occurred at 2,500 mg/d niacin (grade 3 thrombocytopenia and hyperbilirubinemia).
Two DLTs occurred at 2,500 mg/d niacin (grade 3 thrombocytopenia and hyperbilirubinemia).
from: A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and int

1 of 1 paper

A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and interim phase II analysis.